Press Releases

NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients. NGM282, which is a non-tumorigenic, engineered…
Read More...

Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces the approval in Israel of a phase II…
Read More...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for…
Read More...

DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, has acquired 3D printing technology from Tissue Regeneration Systems, Inc. (TRS). The 3D printing…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T)…
Read More...

Agenus Inc. announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034. The open-label, dose-escalation portion of the trial is…
Read More...

uniQure N.V. announced that it will not pursue the renewal of the Glybera (alipogene tiparvovec) marketing authorization in Europe when it is scheduled to expire on October 25, 2017.…
Read More...

H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology…
Read More...

Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, and Upsher-Smith Laboratories, Inc., ("Upsher-Smith"), an established generics manufacturer based…
Read More...

ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced that the Company’s Board of Directors has…
Read More...

A certified CDISC provider and leader in pharmacometrics, Certara has developed a new solution which will enable sponsors to achieve new compliance requirements effortlessly
Read More...

Veeva Systems announced Veeva Vault SiteExchange, a cloud application that allows life sciences companies, CROs, and sites to easily access and exchange information during clinical…
Read More...

Edge Therapeutics, a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that Edge…
Read More...

Regen BioPharma has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen's patented screening methodology…
Read More...

MyoKardia appoints David Meeker, as M.D to the Company’s board of directors. Dr. Meeker is executive VP and head of Sanofi Genzyme, the specialty care global business unit of Sanofi…
Read More...

Mateon announced that from its first schedule analysis from ongoing phase 2/3 Study(FOCUS) in patients with Platinum-resistant Ovarian Cancer result Positive. The analysis was…
Read More...

The US Food and Drug Administration (FDA) has scheduled Puma Biotechnology’s New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on…
Read More...

Roche interim results from the phase III HAVEN 2 study shows emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds in children less than 12 years of…
Read More...

Prometic Life Sciences announced that it has received approval from FDA on the design of the first of its PBI-4050 planned phase 2/3 clinical trials for IPF based on the efficacy data…
Read More...

Ionis Pharmaceuticals announced its collaboration and license agreement with Suzhou Ribo Life Science Co., Ltd. (Ribo) to develop and commercialize RNA-targeted therapeutics in China.…
Read More...